June 24, 2011
Spring has submitted an application for CE Mark approval of its Spring™ Zone Insulin Delivery System.
D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMED)("D. Medical" or "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced that the Company, through its wholly owned subsidiary Spring Health Solution Ltd, has submitted an application for CE Mark approval of its Spring™ Zone Insulin Delivery System. "Spring Zone" replaces D. Medical's first generation Spring ADI insulin pump.
The proprietary Intellispring™ technology, at the heart of the "Spring Zone" Insulin Delivery System, results in unique performance advantages such as superior blockage and detachment detection, environmental (pressure and temperature) adaptability and continuous insulin dose delivery check. This mechanism, backed by the Total Line Control™ (TLC) safety check system, enables failsafe operation and exceptional reliability for continuously controlled and monitored insulin delivery.
Other key design features that differentiate the Spring Zone from all other models on the market make it the smallest, lightest and quietest durable insulin pump.
"Intellispring technology ushers in a new generation of devices for people with diabetes. By eliminating the need for the traditional motor and gear train, the pump user will enjoy greater reliability and extended lifetime use of the device," stated Zoe Myers, Chief Commercial Officer of D. Medical.
Hezkiah Tsoory, D. Medical's Chief Operating Officer, commented, "In addition to the 27 countries of the European Union, we believe that receipt of CE mark approval would support market registrations in other regulated countries, including the five initial target markets for our pump products - Mexico and the BRIC countries of Brazil, Russia, India and China"